

Case-Based Learning Collaborative

October 4, 2024 at 12:00 PM – 1:00 PM

Live In-Person/ Live Virtual

Case-Based Learning Collaborative on Stimulants - 10/04/2024

Overview

The Case-Based Learning Collaborative on Stimulants uses a case-based learning approach to share experiences, educate, and disseminate the latest evidence-based data on the use of medications and other therapies for treating stimulant use disorders. The series provides a reliable forum for providers to network and discuss stimulant use disorders and their treatment to help guide treatment decisions and to destigmatize treatment. Areas of Interest: The sessions in this series are interactive. Faculty speakers present case scenarios to attendees and allow for dialogue and discussion on these cases to support learning. Some of the topics that have been covered include - Medications With Evidence for Treatment of Stimulant Use Disorders and Contingency Management For Treatment Stimulant Use. Upcoming topics for 2024 include Overdose Stimulants and Other Drugs, Deaths and Cardiovascular Sequela Of Stimulant Use, Managing Acute Psychotic Symptoms In Stimulant Use Disorder, Women Who Use Stimulants, Treatment Of Stimulant Use Disorders In Emergency Department, Youth/Adolescents And Stimulant Use Disorders, Opioid Polypharmacy With Stimulants, Criminal Justice Involvement And Stimulant Use, And Pregnancy And Perinatal Care For Women Who Use Stimulants. These series is hosted by UCLA Center for Behavioral and Addiction Medicine (CBAM) in the Department of Family Medicine, in partnership with the LA County Substance Abuse Prevention and Control and the UT Southwestern Clinical Trials Network Big South/West Node.

Learning Objectives

- 1 Interpret and apply information to current practice.
- 2 Identify and describe medication and therapies for treating stimulant use disorders.
- 3 Effectively apply evidence-based therapies in primary care and other settings to improve patient outcomes.
- 4 Effective apply recommendations about treatment of comorbid conditions and polysubstance use when treating stimulant use disorders in practice.
- 5 Effectively address stigma and apply cultural competency when delivering stimulant use disorder treatment and care.
- 6 Describe the practical approaches to harm reduction for stimulant use using medical management and behavioral therapies (e.g. contingency management).

Target Audience

Specialties – Family Medicine, Internal Medicine, Psychiatry And Neurology, Anesthesiology Critical Care Medicine, Emergency Medical Services, Emergency Medicine, Hospice And Palliative Medicine, Internal Medicine-Critical Care Medicine, Medical Toxicology, Neurocritical Care, Pain Medicine, Pediatric Emergency Medicine, Sports Medicine, Undersea And Hyperbaric Medicine, Adolescent Medicine, General Family Medicine, Geriatric Medicine, Health Care Administration, Leadership, And Management*, Hospice And Palliative Medicine, Pain Medicine, Sleep Medicine, Sports Medicine, Adolescent Medicine, Clinical Cardiac Electrophysiology, General Internal Medicine, Infectious Disease, Addiction Psychiatry, Child And Adolescent Psychiatry, Clinical Neurophysiology, Consultation-Liaison Psychiatry, Forensic Psychiatry, Geriatric Psychiatry, Neurocritical Care, Neurology, Neuromuscular Medicine, Pain Medicine, Psychiatry, Sleep Medicine

Professions – Physician, Non-Physician, Addiction Professional, Administrator, Advanced Practice Nurse, Counselor, Dietitian/Nutritionist, Exercise Physiologist, Fellow, Fellow/Resident, Marriage & Family Therapist, Medical Student, Nurse, Nurse Assistant, Occupational Therapist, Other, Pharmacist, Physical Therapist, Physician Assistant, Psychologist, Resident, Resident Care Administrator, Social Worker

Accreditation Statement



The David Geffen School of Medicine at UCLA is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statements

The David Geffen School of Medicine at UCLA designates this live activity for a maximum of 1.00 *AMA PRA Category I Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Statement

The individuals below have been identified as having a position to influence the content of this educational activity. As such, they have disclosed the absence or presence of a relevant financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All of the relevant financial relationships for these individuals have been mitigated.

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
steve shoptaw, Other	Course Director	Grant or research support-Gilead Sciences, Inc. Gilead Sciences, Inc. Gilead Sciences, Inc. - 01/10/2024
Jessica AS Wang, Other	Other Planning Committee Member	Nothing to disclose - 01/10/2024
Julio Meza, Other	Co-Director	Nothing to disclose - 01/12/2024
Jolayemi, Oluwadamilola O., Other	Activity Administrator	Nothing to disclose - 01/09/2024
Giovani V Cruz, Other	Activity Administrator	Nothing to disclose - 01/16/2024
Micah micah.hartwell@okstate.edu, PhD	Faculty	Nothing to disclose - 09/05/2024

Commercial Support

This activity has not received commercial support.

Connect with Us

Center for Continuing Medical Education (CCPD)

ccpd@mednet.ucla.edu

(310) 794-2620